These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 12434710

  • 1. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
    Cheng JW.
    Am J Health Syst Pharm; 2002 Nov 01; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
    [Abstract] [Full Text] [Related]

  • 2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 3. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM.
    Am Heart J; 1999 Oct 17; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [Abstract] [Full Text] [Related]

  • 4. Economic issues in glycoprotein IIb/IIIa receptor therapy.
    Hillegass WB, Newman AR, Raco DL.
    Am Heart J; 1999 Jul 17; 138(1 Pt 2):S24-32. PubMed ID: 10385788
    [Abstract] [Full Text] [Related]

  • 5. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML.
    Circulation; 1999 Nov 16; 100(20):2045-8. PubMed ID: 10562258
    [Abstract] [Full Text] [Related]

  • 6. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM, Califf RM, Topol EJ.
    J Am Coll Cardiol; 2000 Apr 16; 35(5):1103-15. PubMed ID: 10758948
    [Abstract] [Full Text] [Related]

  • 7. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G.
    J Thromb Thrombolysis; 2001 Apr 16; 11(2):99-110. PubMed ID: 11406724
    [Abstract] [Full Text] [Related]

  • 8. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.
    Racine E.
    Am J Health Syst Pharm; 2002 Nov 01; 59(21 Suppl 7):S27-36. PubMed ID: 12434712
    [Abstract] [Full Text] [Related]

  • 9. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Am Heart J; 1998 Apr 01; 135(4):S43-55. PubMed ID: 9539495
    [Abstract] [Full Text] [Related]

  • 10. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
    Kimmelstiel C, Phang R, Rehman A, Rand W, Miele R, Rhofiry J, MacIsaac DA, Gouveia W, Denier D, Becker RC.
    J Thromb Thrombolysis; 2001 May 01; 11(3):203-9. PubMed ID: 11577258
    [Abstract] [Full Text] [Related]

  • 11. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
    Lincoff AM.
    Am J Cardiol; 1998 Oct 22; 82(8B):36P-42P. PubMed ID: 9809890
    [Abstract] [Full Text] [Related]

  • 12. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    McCollam PL, Foster DA, Riesmeyer JS.
    Am J Health Syst Pharm; 2003 Jun 15; 60(12):1251-6. PubMed ID: 12845921
    [Abstract] [Full Text] [Related]

  • 13. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
    Pang JT, Fort S, Della Siega A, Cohen EA.
    J Card Surg; 2002 Jun 15; 17(5):425-31. PubMed ID: 12630543
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Eur Heart J; 1998 Apr 15; 19 Suppl D():D10-21. PubMed ID: 9597518
    [Abstract] [Full Text] [Related]

  • 16. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
    Verdoia M, Pergolini P, Camaro C, Restifo M, Rolla R, Schaffer A, Di Giovine G, Marino P, Bellomo G, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS).
    Blood Coagul Fibrinolysis; 2013 Jun 15; 24(4):411-8. PubMed ID: 23412353
    [Abstract] [Full Text] [Related]

  • 17. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.
    Circ Cardiovasc Interv; 2009 Jun 15; 2(3):230-6. PubMed ID: 20031720
    [Abstract] [Full Text] [Related]

  • 18. IIb's are not IIb's.
    Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM.
    Am J Cardiol; 2000 Apr 27; 85(8A):23C-31C. PubMed ID: 10793177
    [Abstract] [Full Text] [Related]

  • 19. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
    PRICE Investigators.
    Am Heart J; 2001 Mar 27; 141(3):402-9. PubMed ID: 11231437
    [Abstract] [Full Text] [Related]

  • 20. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
    De Luca G, Navarese E, Marino P.
    Eur Heart J; 2009 Nov 27; 30(22):2705-13. PubMed ID: 19875386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.